CBA Florida (CBAI) 10-Q15 May 142014 Q1 Quarterly reportFinancial data

Company Profile

Document_and_Entity_Informatio

Document and Entity Information	3 Months Ended
Document and Entity Information	Mar. 31, 2014
Document And Entity Information	'
Entity Registrant Name	'Cord Blood America, Inc.
Entity Central Index Key	'0001289496
Document Type	'10-Q
Document Period End Date	31-Mar-14
Amendment Flag	'false
Current Fiscal Year End Date	'--12-31
Is Entity a Well-known Seasoned Issuer?	'No
Is Entity a Voluntary Filer?	'No
Is Entity's Reporting Status Current?	'Yes
Entity Filer Category	'Smaller Reporting Company
Entity Common Stock, Shares Outstanding	890,000,000
Document Fiscal Period Focus	'Q1
Document Fiscal Year Focus	'2014

CONDENSED_CONSOLIDATED_BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS (USD $)	Mar. 31, 2014	Dec. 31, 2013
Current assets:	'	'
Cash	$802,496	$708,760
Accounts receivable, net of allowance for doubtful accounts of $93,123 and $88,551	214,546	155,661
Prepaid expenses	163,989	410,276
Other current assets	318,592	378,805
Total current assets	1,499,623	1,653,502
Property and equipment, net $689,573 and $655,962	641,783	653,772
Customer contracts and relationships, net $3,998,300 and $3,850,401	3,345,000	3,492,899
Other Assets	27,422	33,957
Goodwill	244,053	244,053
Total assets	5,757,881	6,078,184
Current liabilities:	'	'
Accounts payable	523,314	592,844
Accrued expenses	1,046,857	1,114,781
Deferred revenue	2,211,870	2,245,132
Derivative Liability	388,507	359,407
Interest on Promissory Notes	420,478	332,155
Promissory notes payable, net of unamortized discount of $16,227 and $58,702	1,495,303	1,441,335
Total current liabilities	6,086,329	6,085,654
Deferred revenue (long term portion)	353,790	362,822
Total liabilities	6,440,119	6,448,476
Stockholders' deficit:	'	'
Preferred stock, $.0001 par value, 5,000,000 shares authorized, no shares issued and outstanding	0	0
Common stock, $.0001 par value, 890,000,000 shares authorized, 890,000,000 and 890,000,000 shares issued and outstanding, inclusive of treasury shares	89,000	89,000
Additional paid-in capital	53,264,971	53,264,971
Common stock held in treasury stock, 20,000 shares	-599,833	-599,833
Accumulated Other Comprehensive income	604,362	410,827
Accumulated deficit	-54,122,144	-53,685,436
Total Cord Blood America stockholders' deficit	-723,614	-520,470
Non-controlling interest	41,376	150,178
Total deficit	-682,238	-370,293
Total liabilities and deficit	$5,757,881	$6,078,184

CONDENSED_CONSOLIDATED_BALANCE1

CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) (USD $)	Mar. 31, 2014	Dec. 31, 2013
Assets	'	'
Allowance for Doubtful accounts Receivables	$93,123	$88,551
Accumulated Amortization and Depreciation	689,573	655,962
Customer contracts and relationship - net of amortization	3,998,300	3,850,401
Liabilities	'	'
Promissory notes payable unamortized discount	$16,227	$58,702
Stockholders Equity	'	'
Preferred stock, par value	$0.00	$0.00
Preferred stock shares authorized	5,000,000	5,000,000
Preferred stock shares issued	0	0
Preferred stock shares outstanding	0	0
Common stock, par value	$0.00	$0.00
Common stock shares authorized	890,000,000	890,000,000
Common stock shares issued	890,000,000	890,000,000
Common stock shares outstanding	890,000,000	890,000,000
Treasury stock	20,000	20,000

CONDENSED_CONSOLIDATED_STATEME

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) (UNAUDITED) (USD $)	3 Months Ended
	Mar. 31, 2014	Mar. 31, 2013
Condensed Consolidated Statements Of Comprehensive Income Loss	'	'
Revenue	$1,415,526	$1,452,138
Cost of services	-439,247	-439,985
Gross Profit	976,279	1,012,153
Administrative and selling expenses	-1,322,478	-1,107,077
Income (loss) from operations	-346,199	-94,924
Interest expense and change in derivative liability	-199,282	-492,996
Net loss from continuing operations before provision for income taxes	-545,481	-587,920
Income taxes	0	0
Net loss from continuing operations after provision for income taxes	-545,481	-587,920
Net Income(Loss)	-545,481	-587,920
Net (income) loss attributable to Non-controlling interest	108,802	36,874
Net Income (loss) attributable to Cord Blood America	-436,679	-551,046
Basic loss per share	'	'
Continuing operations	$0	$0
Discontinued operations	$0	$0
Net basic earning per share	$0	$0
Weighted average common shares outstanding	'	'
Basic weighted average common shares outstanding	890,000,000	503,603,412
Foreign currency translation adjustments	-233,534	34,867
Other comprehensive income, (loss) net of tax	-233,534	34,867
Comprehensive income (loss)	-799,015	-553,053
Non-Controlling interest	108,802	36,874
Comprehensive income (loss) attributable to Cord Blood America	($670,213)	($576,179)

CONDENSED_CONSOLIDATED_STATEME1

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) (USD $)	3 Months Ended
	Mar. 31, 2014	Mar. 31, 2013
CASH FLOWS FROM OPERATING ACTIVITIES:	'	'
Consolidated net loss	($545,481)	($587,920)
Adjustments to reconcile net loss to net cash used in operating activities:	'	'
Amortization of loan discount	53,968	143,521
Depreciation and amortization	181,141	193,397
Change in value of derivative liability	29,100	256,394
Shares issued as payment of interest on convertible notes	'	47,611
Bad debt	943	5,965
Changes in accounts receivable	-190,205	'
Changes in other current asset	3,226	'
Changes in deferred tax asset	12,386	'
Changes in prepaid	85,293	'
Changes in accounts payable	81,556	'
Changes in accrued expense	111,539	'
Changes in accrued interest	88,323	'
Changes in deferred revenue	310,645	'
Net Change in operating assets and liabilities	0	35,135
NET CASH PROVIDED BY OPERATING ACTIVITIES OF CONTINUING OPERATIONS	222,434	94,103
CASH FLOWS FROM INVESTING ACTIVITIES	'	'
Payments for purchase of property and equipment	-118,481	-129,160
NET CASH USED IN INVESTNG ACTIVITIES OF CONTINUING OPERATIONS	-118,481	-129,160
NET INCREASE (DECREASE) IN CASH	4,735	-190
Cash balance at beginning of period	708,760	393,832
Cash balance at end of period	802,496	393,642
Supplemental Disclosures	'	'
Interest Paid	$0	$0
Conversion of debt into common shares	0	410,910

Organization_and_Description_o

Organization and Description of Business	3 Months Ended
	Mar. 31, 2014
Notes to Financial Statements	'
NOTE 1 - Organization and Description of Business	'
	Cord Blood America, Inc. ("CBAI" or the “Company”), formerly D&A Lending, Inc., was incorporated in the State of Florida on October 12, 1999. In October, 2009, CBAI re-located its headquarters from Los Angeles, California to Las Vegas, Nevada. CBAI's wholly-owned subsidiaries include Cord Partners, Inc., CorCell Companies, Inc., CorCell, Ltd., (Cord Partners, Inc., CorCell Companies, Inc. and CorCell, Ltd. are sometimes referred to herein collectively as “Cord”), CBA Properties, Inc. ("Properties"), and Career Channel, Inc. formerly D/B/A Rainmakers International ("Rain"). In September 2010, CBAI purchased a majority interest in Biocordcell Argentina S.A. (“Bio”). CBAI and its subsidiaries engage in the following business activities:

	●	CBAI and Cord specializes in providing private cord blood and cord tissue stem cell storage services to families throughout the United States and Puerto Rico.

	●	Biocordcell Argentina S.A. specializes in providing private cord blood stem cell storage to families in Argentina, Uruguay and Paraguay.

	●	Properties was formed to hold corporate trademarks and other intellectual property.

	The accompanying consolidated financial statements have been prepared on a going-concern basis, which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of business. The accompanying consolidated financial statements do not include any adjustments relating to the recoverability and classification of assets and liabilities that may be necessary in the event CBAI cannot continue as a going concern.

Summary_of_Significant_Account

Summary of Significant Accounting Policies

3 Months Ended

Mar. 31, 2014

Notes to Financial Statements

NOTE 2 - Summary of Significant Accounting Policies

Basis of Presentation and Going Concern

The accompanying financial statements of CBAI and its subsidiaries have been prepared in accordance with accounting principles generally accepted in the United States of America, which contemplate continuation of the Company as a going concern. The Company has experienced recurring net losses from operations, which losses have caused an accumulated deficit of approximately $54.12 million as of March 31, 2014. In addition, CBAI has notes and loans payable of approximately $1.49 million as of March 31, 2014. The Company has no available common stock outstanding as of March 31, 2014, and as such, the Company may not be able to issue common stock to retire debt until such time as the shareholders approve an increase in the number of shares authorized. These factors, among others, raise substantial doubt about CBAI's ability to continue as a going concern.

Since inception, the Company has financed cash flow requirements through the issuance of common stock and warrants for cash, services and loans. However, over the past eight quarters, the Company has reduced operating expenses, ended investment in its unconsolidated affiliates and Stellacure, and received no additional funding from outside sources for working capital. During the quarter ended March 31, 2014 the Company had positive cash flow from operations of $0.22 million. The Company plans to continue to operate on its cash flows from operations by aligning its expenses with its revenues. If cash flows from operations are significantly less than projected, then the Company would need to either cut back on its budgeted spending, look to outside sources for additional funding or a combination of the two. The Company currently does not have any financing agreements in place for additional funding. If the Company is unable to access sufficient funds when needed, obtain additional external funding or generate sufficient revenue from the sale of our products, it could be forced to curtail or possibly cease operations.

In view of these conditions, CBAI's ability to continue as a going concern is dependent upon its ability to meet its financing requirements, and to ultimately achieve profitable operations. Management believes that its current and future plans provide an opportunity to continue as a going concern. The accompanying consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded assets, or the amounts and classification of liabilities that may be necessary in the event CBAI cannot continue as a going concern.

Basis of Consolidation

The consolidated financial statements include the accounts of CBAI and its wholly-owned and majority-owned subsidiaries, Cord and Biocordcell Argentina S.A. All significant inter-company balances and transactions have been eliminated upon consolidation

Deferred Revenue

Deferred revenue consists of payments for enrollment in the program and processing of umbilical cord blood and cord tissue by customers whose samples have not yet been collected, as well as the pro-rata share of annual storage fees for customers whose samples were stored during the year.

Valuation of Derivative Instruments

ASC 815-40 (formerly SFAS No. 133 "Accounting for derivative instruments and hedging activities"), requires that embedded derivative instruments be bifurcated and assessed, along with free-standing derivative instruments such as warrants, on their issuance date and in accordance with ASC 815-40-15 (formerly EITF 00-19 "Accounting for derivative financial instruments indexed to, and potentially settled in, a company's own stock") to determine whether they should be considered a derivative liability and measured at their fair value for accounting purposes. In determining the appropriate fair value, the Company uses the Black-Scholes option pricing formula. At March 31, 2014, the Company adjusted its derivative liability to its fair value, and reflected the change in fair value, in its consolidated statement of operation and comprehensive loss.

Revenue Recognition

CBAI recognizes revenue under the provisions of ASC 605-25 (previously Staff Accounting Bulletin 104 “Revenue Recognition”). CBAI provides a combination of products and services to customers. This combination arrangement is evaluated under ASC 605-25-25 (previously Emerging Issues Task Force Issue No. 00-21, "Revenue Arrangements with Multiple Deliverables"). ASC 605-25-25 addresses certain aspects of accounting for arrangements under multiple revenue generating activities.

Cord and Bio recognize revenue from both enrollment fees and processing fees upon the completion of processing while revenue from storage fees are recognized ratably over the contractual storage period.

Franchise revenues are recognized in accordance with ASC 952-605-3, according to requirements for recognizing franchise revenues after “franchise agreement” services are completed and substantially performed. Further, in accordance with ASC 952-605-25-7, the installment or cost recovery accounting method is used to account for franchise fee revenue only in those exceptional cases when revenue is collectible over an extended period and no reasonable basis exists for estimated collectability. During the quarter ended March 31, 2014, the Company did not recognize any franchise revenues.

Impairment of Long-Lived Assets

Long-lived assets, other than goodwill, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of the assets might not be recoverable. Conditions that would necessitate an impairment assessment include a significant decline in the observable market value of an asset, a significant change in the extent or manner in which an asset is used, or a significant adverse change that would indicate that the carrying amount of an asset or group of assets is not recoverable. For long-lived assets to be held and used, the Company recognizes an impairment loss only if its carrying amount is not recoverable through its undiscounted cash flows and measures the impairment loss based on the difference between the carrying amount and fair value. The Company reviews goodwill for impairment at least annually or whenever events or circumstances are more likely than not to reduce the fair value of goodwill below its carrying amount.

Equity Investments

Cord had a non-controlling equity investment in ViviCells International, Inc., a privately held company in the business of providing cord blood stem cell and adult peripheral blood stem cell preservation services. The Company utilized the equity method of accounting as it owned more than 20% of the outstanding common stock and had the ability to exercise significant influence over this company. As such, the investment was carried at cost less Cord's proportionate share of ViviCells net loss for the period since investment. During 2011 the Company foreclosed on and acquired all the assets of Neocells, a subsidiary of ViviCells, as satisfaction on the outstanding receivable from ViviCells. There is no remaining investment in ViviCells as of December 31, 2012 because of this action.

Cord has a minority equity investment in China Stem Cells, Ltd., a Cayman Islands Company, a privately held company organized to conduct a stem cell storage business in China. In 2011, Cord acquired a minority equity investment in VidaPlus, an umbilical cord processing and storage company. The Company utilizes the cost method of accounting as it owns less than 20% of the outstanding common stock and only has the ability to exercise nominal, not significant, influence over these companies. The cost of this investment was $204,062 and represents 7% equity in Vivicells. As of December 31, 2013, the Company recognized an impairment loss on the Vidaplus investments and notes receivable, and wrote-down its equity interest and notes receivable value to $0.

Fair Value Measurements

Assets and liabilities recorded at fair value in the consolidated balance sheets are categorized based upon the level of judgment associated with the inputs used to measure the fair value. Level inputs, as defined by ASC 820-10, are as follows:

●

Level 1 – quoted prices in active markets for identical assets or liabilities.

●

Level 2 – other significant observable inputs for the assets or liabilities through corroboration with market data at the measurement date.

●

Level 3 – significant unobservable inputs that reflect management’s best estimate of what market participants would use to price the assets or liabilities at the measurement date.

The following table summarizes fair value measurements by level at March 31, 2014 of assets and liabilities measured at fair value on a recurring basis:

Level 1

Level 2

Level 3

Total

Cash and cash equivalents

802,496

—

802,496

Derivative liability

—

(388,507

)

(388,507

)

Derivative liability was valued under the Black-Scholes model, consistent with last year, with the following assumptions:

Risk free interest rate

0 to 0.13 %

Expected life

0 to 1 years

Dividend Yield

Volatility

0% to 112%

The following is a reconciliation of the derivative liability:

Value at December 31, 2013

359,407

Change in value of derivative

29,100

Value at March 31, 2014

388,507

For certain parts of the Company’s financial instruments, including cash, accounts receivable, prepaid expenses and other assets, accounts payable and accrued expenses, and deferred revenues, the carrying amounts approximate fair value due to their short maturities. The carrying amounts of the Company’s notes receivable and notes payable approximates fair value based on the prevailing interest rates.

Recently Issued Accounting Pronouncements

In February 2013, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") 2013-02, Reporting of Amounts Reclassified Out of Accumulated Other Comprehensive Income, ("ASU 2013-02"). ASU 2013-02 amends Accounting Standards Codification ("ASC") 220, Comprehensive income ("ASC 220"), and requires entities to present the changes in the components of accumulated other comprehensive income for the current period. Entities are required to present separately the amount of the change that is due to reclassifications, and the amount that is due to current period other comprehensive income. These changes are permitted to be shown either before or net-of-tax and can be displayed either on the face of the financial statements or in the footnotes. ASU 2013-02 was effective for the Company's interim and annual periods beginning January 1, 2013. The adoption of ASU 2013-02 did not have a material effect on the Company's consolidated financial position or results of operations.

In March 2013, the FASB issued new guidance related to the release of cumulative translation adjustment related to an entity's investment in a foreign entity. The guidance clarifies that the guidance in Subtopic 830-30, Foreign Currency Matters - Translation of Financial Statements, applies to the release of cumulative translation adjustment into net income when a reporting entity either sells a part or all of its investment in a foreign entity or ceases to have a controlling financial interest in a subsidiary or group of assets that constitute a business within a foreign entity. This guidance is effective for the Company prospectively for reporting periods beginning October 1, 2014. The adoption of this guidance is not expected to have a material impact on the Company's consolidated financial statements.

In April 2013, the FASB issued ASU 2013-07, Presentation of Financial Statements (Topic 205): Liquidation Basis of Accounting. ASU 2013-07 clarifies when an entity should apply the liquidation basis of accounting. ASU 2013-07 also provides principles for the recognition and measurement of assets and liabilities and requirements for financial statements prepared using the liquidation basis of accounting. ASU 2013-07 is effective for fiscal years and interim periods within those years beginning after December 15, 2013. The Company does not expect amendments in ASU 2013-07 to impact the Company's financial statements, results of operations or liquidity.

In July 2013, the FASB issued ASU 2013-11, Income Taxes (Topic 740): Presentation of an Unrecognized Tax Benefit When a Net Operating Loss Carryforward, a Similar Tax Loss, or a Tax Credit Carryforward Exists, which eliminates diversity in practice for the presentation of an unrecognized tax benefit when a net operating loss carryforward, a similar tax loss or a tax credit carryforward is available to reduce the taxable income or tax payable that would result from disallowance of a tax position. ASU 2013-11 affects only the presentation of such amounts in an entity’s balance sheet and is effective for fiscal years beginning after December 15, 2013 and interim periods within those years. Early adoption is permitted. The adoption of this guidance is not expected to have a material impact on the Company’s consolidated financial statements.

Notes_and_Loans_Payable

Notes and Loans Payable	3 Months Ended
	Mar. 31, 2014
Notes to Financial Statements	'
NOTE 3 - Notes and Loans Payable	'

	Note 3. Notes and Loans Payable

	At March 31, 2014 and December 31, 2013 notes and loans payable consist of:

		March 31,			December 31,
		2014			2013

	Convertible Promissory Note Payable to St. George Investment, secured by the Company’s assets, interest rate of 6.0% per annum, with payment due on or before March 10, 2015		259,530			259,530
			1,252,000			1,252,000
	Secured Convertible Promissory Note to Tonaquint, Inc., 6% per annum; due on or before February 27, 2014
	(See Item 1. Legal Proceedings as described more fully)
			1,511,530			1,511,530
	Less: Unamortized Discount		(16,227	)		(70,195	)
		$	1,495,303		$	1,441,335

Commitments_and_Contingencies

Commitments and Contingencies	3 Months Ended
	Mar. 31, 2014
Notes to Financial Statements	'
NOTE 4 - Commitments and Contingencies	'
	St. George Investments

	On March 10, 2011, the Company entered into a Note and Warrant Purchase Agreement (the "Purchase Agreement") with St. George Investments, LLC, (“St. George”) an Illinois limited liability company (the "Investor") whereby the Company issued and sold, and the Investor purchased: (i) Secured Convertible Promissory Notes of the Company in the principal amount of $1,105,500 (the "Company Note") and (ii) a Warrant to purchase common stock of the Company (the "Warrant"). The Investor paid $250,000 in cash as an initial payment to the Company and executed and delivered six separate “Secured Buyer Notes” (the “Buyer Notes”), as consideration in full for the issuance and sale of the Company Note and Warrants.

	The principal amount of the Company Note is $1,105,500 ("Maturity Amount") and the Company Note is due 48 months from the issuance date of March 10, 2011. The Company Note has an interest rate of 6.0%, which would increase to a rate of 12.0% on the happening of certain Trigger Events, including but not limited to: a decline in the 10-day trailing average daily dollar volume of the common shares in the Company’s primary market to less than $30,000 of volume per day at any time; the failure by the Company or its transfer agent to deliver Conversion Shares (defined in the Company Note) within 5 days of Company’s receipt of a Conversion Notice (defined in the Company Note). Due to a triggering event occurring, the current interest rate is 12%. The total amount funded (in cash and notes) was $1,000,000, representing the Maturity Amount less an original issue discount of $100,500 and the payment of $5,000 to the Investor to cover its fees, with payment consisting of $250,000 advanced at closing and $750,000 in a series of six secured convertible Buyer Notes of $125,000 each, with interest rates of 5.0%. To date, St. George has paid the total amount due.

	The Buyer Notes are secured by an Irrevocable Standby Letter of Credit (“Letter of Credit”). The warrant also contains a net exercise /cashless exercise provision. St. George may elect to convert all or part of the principal and any accrued unpaid interest on the Company Note on or before the aforementioned maturity date, subject to certain limitations. The conversion price under the Company Note is eighty percent (80%) of the average of the closing bid prices for the three (3) Trading Days (defined in the Purchase Agreement) with the lowest closing bids over the twenty (20) Trading Days immediately preceding the Conversion Date (defined in the Company Note), subject to adjustments as set forth in the Company Note. Due to adjustments, St. George’s current conversion ratio inserts fifty-five percent (55%) in the aforementioned formula, in place of eighty percent (80%).

	The Investor has also received a five year warrant entitling it to purchase shares of common stock of the Company at an exercise price determined under the terms of the Warrant. The warrant also contains a net exercise /cashless exercise provision.

	As of March 31, 2014 the balance due to St. George Investments was $259,530 in principal and $24,563 in accrued interest.

	The Company Note, Warrant and related documentation, including any amounts owed by the Company to St. George based thereon, are in dispute and are the subject of litigation, as described more fully in Item 1. Legal Proceedings.

	Tonaquint, Inc.

	In a transaction that closed on June 29, 2012, the Company entered into a Securities Purchase Agreement (the "Purchase Agreement") with Tonaquint, Inc. (“Tonaquint”) a Utah corporation whereby the Company issued and sold, and Tonaquint purchased a Secured Convertible Promissory Note of the Company in the principal amount of $1,252,000 (the "Company Note").

	The Company Note was issued June 27, 2012 and is due 20 calendar months after the issuance date. The Company Note has an interest rate of 6.0%, which would increase to a rate of 18.0% on the happening of certain Events of Default (defined in the Company Note), including but not limited to: failure to pay and the failure by the Company or its transfer agent to deliver Conversion Shares (defined in the Company Note) within 3 Trading Days of the Company’s receipt of a Conversion Notice (defined in the Company Note). Tonaquint has claimed an interest rate of 18%, which is being disputed by the Company. The total amount funded in cash at closing was $1,120,000, representing the principal amount less an original issue discount of $112,000 and the payment of $20,000 to Tonaquint to cover its fees.

	Tonaquint has the right to convert, subject to restrictions described in the Company Note, all or a portion of the outstanding amount of the Company Note into shares of the Company’s common stock at a price of $0.03. So long as Tonaquint has not extinguished the Company Note in its entirety pursuant to such conversions, the Company shall make monthly payments to Tonaquint on the Company Note, through either the issuance of shares of the Company’s common stock or by payment in cash, at the election of the Company. Payments commence six months from the date of issuance of the Company Note and continue until the Company Note has been paid in full. The amount of the monthly payments is the greater of (i) $100,000, plus the sum of any accrued and unpaid interest as of the applicable Installment Date (defined in the Company Note) and accrued and unpaid Late Charges (defined in the Company Note), if any, under the Company Note as of the applicable Installment Date (defined in the Company Note), and any other amounts accruing or owing to Investor under the Company Note as of such Installment Date, or (ii) the then-outstanding balance of the Company Note divided by the number of Installment Dates remaining prior to the Maturity Date.

	In the event the Company is unable to make payments in cash or otherwise elects not to make a payment or payments in cash, the number of common shares delivered to the Investor upon conversion will be calculated by dividing the amount of the Company Note that is being converted by the market price of the common stock, which is defined as 80% of the arithmetic average of the three (3) lowest volume weighted average prices of the shares of the Company’s common stock during the twenty three (23) consecutive trading day period immediately preceding the date as of which such price determination is required (such as the effective date of a conversion).

	As of March 31, 2014, the amount owed to Tonaquint was $1,252,000 of principal and $395,915 in accrued interest in accordance with Tonaquint’s claim which is being disputed by the Company.

	The Company Note, Purchase Agreement and other related documents, including any amounts owed by the Company to Tonaquint based thereon, are in dispute and are the subject of litigation, as described more fully in Item 1. Legal Proceedings.

	VidaPlus

	On January 24, 2011, the Company entered into a Stock Purchase Agreement to acquire up to 51% of the capital stock in VidaPlus, an umbilical cord processing and storage company headquartered in Madrid, Spain. The Agreement is organized into three tranches; the first executed at closing with an initial investment of approximately $204,000 (150,000 Euro) for an amount equivalent to 7% as follows; 1% of share capital in initial equity or approximately $30,000 and 6% or an estimated $174,000 as a loan convertible into equity within 12 months of closing. The initial investment was secured by a Pledge Agreement on 270 VidaPlus samples that are incurring annual storage fees. The second tranche provides the opportunity for an additional 28% in share capital through monthly investments based on the number of samples processed in that month (up to a maximum of 550,000 EUR). In connection with Tranche 2, the Company has loaned VidaPlus $246,525 to date. Converting the investment from a loan into equity will take place within 24 months of the date the amount of shares due to the Company pursuant to the second tranche is calculated. The third tranche follows a similar loan to equity agreement as tranche two but for an additional 16% equity at the option of the Company (up to a maximum of 550,000 EUR). VidaPlus contracts through Stellacure and their relationship with the German Red Cross for their processing and storage.

	In connection with the VidaPlus Stock Purchase Agreement entered into on January 24, 2011, the Company is obligated to make monthly loans to VidaPlus based on the number of new samples processed and up to a maximum of 550,000 Euro for each of Tranche 2 and 3 of the Agreement. Tranche 2 did contain provisions that provided the Company an option to discontinue funding if certain performance targets were not met.

	In January 2012, the Company exercised its right to convert its Tranche 1 loan into 6% of the outstanding shares of VidaPlus, and as a result, the Company owns a total of 7% of the outstanding shares. At the time of the equity conversion, the Company no longer maintained its Pledge on the 270 VidaPlus samples associated with Tranche 1; however, the Company maintained a liquidation preference in VidaPlus over the money invested by the Company in VidaPlus. Additionally, the Company declined to make any further investment (loan or otherwise) to VidaPlus under whether Tranche 2, Tranche 3 or otherwise. CBAI holds a pledge over the umbilical cord blood maintenance and storage contracts between VidaPlus and certain of its customers, and all rights contained therein, including but not limited to the rights to administer those contracts and the rights to collect the revenues derived from those contracts, for 328 samples. CBAI holds that pledge until such time as it converts the monies paid to VidaPlus under Tranche 2 of the Stock Purchase Agreement into equity into Vidaplus, in accordance with the formulas set forth in the Stock Purchase Agreement. CBAI must make that conversion within two years of when the calculation was made as to the amount of shares to which CBAI is entitled pursuant to Tranche 2, which means that such conversion shall take place around or before February 2014. CBAI also holds a liquidation preference in VidaPlus for the money the Company invested in VidaPlus. On February 14, 2014, CBAI delivered to VidaPlus its election to convert its loan under Tranche 2 into shares of stock in VidaPlus.

	Patent License Agreement

	PharmaStem Therapeutics claims to hold certain patents relating to the storage, expansion and use of hematopoietic stem cells. In the past several years, PharmaStem has commenced suit against numerous companies involved in cord blood collection and preservation alleging infringement of its patents. In October 2003, after a jury trial, judgment was entered against certain of our competitors and in favor of PharmaStem in one of those suits. In February 2004, PharmaStem commenced suit against Cord Partners and certain of its competitors alleging infringement of its patents. Management of Cord Partners determined to settle, rather than to litigate, this matter. As a result, PharmaStem and Cord Partners entered into a Patent License Agreement in March 2004. Pursuant to the Patent License Agreement, Cord Partners could, on a non-exclusive basis, collect, process and store cord blood utilizing PharmaStem’s claimed technology and processes allegedly covered by its patents for so long as the patents may remain in effect. Most of the patents at issue expired in 2010. PharmaStem could claim, arguendo, Cord Partners is obligated under the Patent License Agreement to pay royalties to PharmaStem of 15% of all revenues generated by Cord Partners from the collection and storage of cord blood on and after January 1, 2004. Other than, potentially royalties, which would be disputed by Cord, no amount is payable by Cord Partners to PharmaStem. All litigation between the parties was dismissed and all prior claims were released. As of 2008, Cord ceased paying all royalties to PharmaStem. The patents have been declared void under a final decision on appeal, and as such, there is no pending litigation in this matter. As of March 31, 2014, the Company included approximately $226,000 in accounts payable and $120,000 included in accrued expenses to account for this liability since 2008, though the Company disputes that it owes any royalties to Pharmastem.

	Commitments and Contingencies

	BioCells

	In September 2010, the Company entered into a Stock Purchase Agreement (the “Agreement”), with the Shareholders of Biocordcell Argentina S.A., a corporation organized under the laws of Argentina (“Bio”), providing for the Company’s acquisition of 50.1% of the outstanding shares of Bio (the “Shares).

	Under the Agreement, the Company paid $375,000 in cash at the closing, and was obligated to pay an additional $350,000 in October, 2010, $150,000 of which is part of the fixed portion of the purchase price for the shares, for a total minimum purchase price of $525,000. The remaining $200,000 of this payment represents advances against the contingent payments due based on Bio’s 2010 and 2011 net income performances. In 2011, the Company negotiated and paid out the amount of $500,000 in connection with the 2010 earn out.

	As of June 22, 2012, the Company entered into an Agreement with the shareholders of Bio from whom the Company purchased its majority ownership interest in Bio in 2010 (the "Sellers") relating to the 2011 earn out. Under the Agreement, the Company was to pay the Sellers the following: $25,000 on or before June 30, 2012; $10,000 on or before July 31, 2012; and $25,000 on or before September 30, 2012, for a total cash payment of $60,000. In addition, the Sellers will collect the Company’s portion of BioCells shareholders’ dividends for fiscal years 2012 and 2013, up to a maximum amount of $440,000, if any. There were no shareholder dividends earned or paid for the 2012 and 2013 fiscal years. Also, since BioCells was not sold before April 2014, certain thresholds for purchase price and payment were not met or exceeded, and the Sellers did not receive compensation. As a result of this Agreement with the Sellers of BioCells, the Company has paid the total cash amount due of $60,000 as of December 31, 2012 and there have been no earned portion of Company’s dividends paid to Sellers for fiscal years 2012 and 2013.

	Employment Agreements

	On September 12, 2011 (the “Company”), entered into an Executive Employment Agreement with Joseph R. Vicente, then the Company’s Chief Operating Officer and Vice President and appointed Chairman and President on May 15, 2012 by the Board of Directors, which was effective as of August 1, 2011 and shall terminate as of December 31, 2014, unless earlier terminated by the Company or Mr. Vicente. Mr. Vicente’s Executive Employment Contract had an initial term from August 1, 2011 through December 31, 2011, and is renewable annually thereafter for up to three additional, successive years, and provides for a base salary equal to his previous year’s annual salary, which said salary was set under the provisions of the previous employment agreement entered between Mr. Vicente and the Company in July of 2008. Mr. Vicente voluntarily reduced his annual salary by 12.5% until otherwise determined by Mr. Vicente, along with the advice and consent of the Company’s Board of Directors. It also provides for an annual bonus, payable at the discretion of the Board of Directors, equal to 25% of Mr. Vicente’s prior year base salary. The Agreement provides for a change of control termination bonus, which provide that if Mr. Vicente is terminated, his compensation reduced, or Mr. Vicente terminates his employment within one year after a change of control, then Mr. Vicente is entitled to a termination benefit in an amount equal to the average annual cash compensation over the three (3) year period preceding the Triggering Event (defined in the agreements) multiplied (2.00). The Agreement also provides for termination payments in the absence of a change of control in the event the Company terminates Mr. Vicente without cause in an amount equal to all compensation paid by the Company to Mr. Vicente for the 24 months preceding the termination, along with health plan and 401k incentives (if any were to be offered – the Company terminated its 401k earlier in 2012), as stated in the agreement.

	The Company entered into an Executive Employment Agreement with Stephen Morgan (the “Employee”) on August 10, 2012, with July 1, 2012 as the effective date of the Agreement. The Agreement provides for a change of control termination bonus, whereby if the Employee is terminated, his compensation reduced, or the Company terminates the Employee’s employment within one year after a change in control, then the Employee is entitled to a termination benefit in an amount equal to the employee’s cash compensation over the one (1) year preceding the Triggering Event (defined in the Agreement). The Agreement also provides for termination payments in the absence of a change of control in the event the Company terminates the Employee without cause in an amount equal to all compensation paid by the Company to the Employee for the 12 months preceding the termination, along with health plan and 401k incentives (if any were to be offered – the Company terminated its 401k earlier in 2012), as stated in the Agreement. The Agreement provides for an annual salary of $125,000, along with a bonus, payable at the discretion of the Board of Directors of up to an annual amount of 20% of the Employee’s salary. Mr. Morgan’s compensation, as set forth in the Agreement has not increased as a result of his election to the officer positions of Vice President and Secretary on May 15, 2012 in addition to his retention of his previous position, General Counsel. The Company believes the assumption of additional roles by existing management and other individuals in leadership positions, including filling recently vacated roles, will reduce overall management costs while also leading to greater efficiency within the organization.

	Operating Leases

	On January 21, 2014, the Company entered a First Amendment to Lease, which extended its lease at the property located at 1857 Helm Drive, Las Vegas, Nevada through September 30, 2019. In connection with the amendment, the Company received an abatement of the entire amount of its rent for January 2014, except for CAM charges. In addition, as of October 1, 2014, the Company’s monthly lease payments shall revert back to their rates as they existed in June 2009, other than CAM charges, with annual adjustments thereafter as set forth in the Amendment. Moreover, the Landlord has the option to lease a portion of the premises currently occupied by the Company to a third party, and if this portion is leased to a third party, the Company’s monthly rent amount shall be reduced pro rata with the portion of the space leased to a third party. If the Landlord is unable to or elects not to lease a portion of the premises to a third party by November 30, 2015 and by each subsequent anniversary thereof, the Company shall receive an additional abatement of one month rent, excluding CAM charges, in December 2015, December 2016 and December 2017, respectively and as applicable. CBAI’s subsidiary leases office space in Argentina, (Bio). The lease for Bio is for three years beginning in May 2014, and Bio shall receive rent abatement for May and June of 2014.

	Commitments for future minimum rental payments, by year, and in the aggregate, to be paid under such operating lease as of March 31, 2014, are as follows:

			Rent
		to be paid
2014		$	169,083
2015			232,064
2016			244,943
2017			199,109
2018			189,842
Thereafter			153,902
Total		$	1,188,943

Related_Party_Transactions_and

Related Party Transactions and Commitments	3 Months Ended
Related Party Transactions and Commitments	Mar. 31, 2014
Notes to Financial Statements	'
NOTE 5 - Related Party Transactions and Commitments	'
	China Stem Cells, Ltd.

	In March of 2010 the Company acquired pursuant to a License Agreement, a 10% non dilutable interest in what became, in December 2010, China Stem Cells, Ltd., a Cayman Islands Company (hereinafter "Cayman"), which indirectly holds a 100% capital interest in AXM Shenyang, a company organized to conduct a Stem Cell Storage Business in China. In exchange for issuance of an equity interest in Cayman, under the terms of the Transfer of Technology Agreement the Company agreed to provide technology transfer, knowhow and training in the setup, marketing and operation of the China Stem Cell Storage business. In connection with the License Agreement, the Company is to receive royalties equal to 8.5% of "Net Revenues" realized from the China Stem Cell Storage business, over the 15 year term of the agreement, with certain minimum annual royalties’ payable beginning in 2011. The Company has not been paid any royalty balance due to date, and it remains doubtful that any such royalties will be collected.

	In December of 2010 the Company also acquired the option to provide up to $750,000 of additional capital funding to Cayman through the purchase of Cayman Secured Convertible Promissory Notes and attached Cayman Warrants to acquire its Common Stock. Other Cayman shareholders were granted similar options, with the intent of raising the aggregate up to $1.5 million in additional capital for Cayman and its subsidiaries. CBAI has exercised this option in part, provided a total of $400,000 in additional capital to Cayman, and is to receive Cayman Secured Convertible Promissory Notes for this sum along with 80 Cayman (TBD) Warrants. The Secured Convertible Promissory Notes are convertible into Cayman stock at a conversion price of $1,500 per share, subject to certain adjustments. The Warrants have a five year term and are exercisable at an option exercise price of $0.05 per share per share, subject to certain adjustments. The Company has recorded a reserve for the entire carrying amount of the receivable, including interest. The Company’s current President, Joseph Vicente was appointed as a Director of China Stem Cells Ltd. in July 2012.

	VidaPlus

	The Company holds 7% of the outstanding shares of VidaPlus, and has a balance of convertible loans receivable amounting to $246,525. During the year ended December 31, 2012, the Company reviewed the recoverability of the equity investment and loans receivable and the carrying amount exceeds the fair value of the investment as a result of recurring and continued operating losses at VidaPlus. Fair value of the loans receivable is determined based on the discounted future net cash flows expected to be generated by assets pledged against the loans. The Company recorded an impairment of 100% of the book value of the equity investment and convertible loan receivable.

	Frozen Food Gift Group, Inc.

	CBAI engaged Frozen Food Gift Group, Inc. (“FFGG”) as a vendor, prepaying for $45,000 in products during the year ended December 31, 2011. The remaining balance on that account is $30,655 as of March 31, 2013, not including additional interest and fees to which the Company may be entitled. The Company’s former CEO and Chairman of the Board, Mathew Schissler who resigned effective May 14, 2012, owned 36.2% of the outstanding shares of FFGG based on an S-1 filing made by that company with the SEC on July 31, 2012, and on information and belief is FFGG’s Chairman of the Board. CBAI’s former COO, and now President Joseph Vicente served on the Board of Directors of FFGG, but resigned effective as of January 26, 2012.

	The Company entered into a Release with FFGG effective as of March 5, 2014, with the mutual releases and negative covenants contained therein not taking effect until such time as the Company received payment under the Claim Purchase Agreement, entered as of March 12, 2014 with a third party to the Company in exchange for the Company’s claims against FFGG.

Share_Based_Compensation

Share Based Compensation	3 Months Ended
Share Based Compensation	Mar. 31, 2014
Notes to Financial Statements	'
NOTE 6 - Share Based Compensation	'
	Stock Option Plan

	The Company's Stock Option Plan permits the granting of stock options to its employees, directors, consultants and independent contractors for up to 8.0 million shares of its common stock. The Company believes that such awards encourage employees to remain employed by the Company and also to attract persons of exceptional ability to become employees of the Company. On July 13, 2009, the Company registered its 2009 Flexible Stock Plan, which increases the total shares available to 4 million common shares. The agreement allows the Company to issue either stock options or common shares from this Plan.

	On June 3, 2011, the Company registered its 2011 Flexible Stock Option plan, and reserved 1,000,000 shares of the Company's common stock for future issuance under the Plan. The Company canceled the Company's 2010 Flexible Stock Plan, and returned 501,991 reserved but unused common shares back to its treasury.



	Stock options that vest at the end of a one-year period are amortized over the vesting period using the straight-line method. For stock options awarded using graded vesting, the expense is recorded at the beginning of each year in which a percentage of the options vests. The Company did not issue any stock options for the period ended March 31, 2014.

	The Company’s stock option activity was as follows:

			Stock				Weighted Average Exercise Price				Weighted Avg. Contractual
			Options				Weighted Average Exercise Price				Remaining Life

	Outstanding, January 1, 2013			6,323,570				1.01				5.76
	Granted			-				-				-
	Exercised			-				-				-
	Forfeited/Expired			627,740				-				-
	Outstanding, December 31, 2013			5,570,830				1.01				4.51
	Exercisable at December 31, 2013			5,570,830				1.01				4.51
	Forfeited/Expired			-				-				-
	Outstanding, March 31, 2014			5,570,830				1.01
	Exercisable at March 31, 2014			5,570,830				1.01				4.26

	The following table summarizes significant ranges of outstanding stock options under the stock option plan at March 31, 2014:

	Range of				Number of				Weighted Average				Weighted Average		Number of		Weighted Average
	Exercise Prices				Options				Remaining				Exercise		Options		Exercise
									Contractual Life				Price		Exercisable		Price
									(years)
	$	0.33 — 20.00				5,522,806				4.28			$	0.83		5,522,806	$	0.83
	$	21.00 — 30.00				30,126				0.87				25		30,126		25
	$	31.00— 51.00				17,898				4.26				31.21		17,898		31.21
						5,570,830				4.26			$	1.01		5,570,830	$	1.01

	A summary of the activity for unvested employee stock options as of March 31, 2014 and changes during the period presented below:

	Weighted Average Grant Date Fair Value per Share

			Stock				Weighted Avg. Grant Date Fair Value per Share
			Options				Weighted Avg. Grant Date Fair Value per Share
	Nonvested at January 1, 2014			--				0.39
	Granted			--				--
	Vested			--				--
	Exercised			--				--
	Cancelled			--				--
	Pre-vested forfeitures			--				--
	Nonvested at March 31, 2014			--				0.39

	The total compensation cost related to non-vested options amounts to $0. All outstanding unexercised options provide for adjustment upon stock split, as well as under certain other circumstances.

Warrant_Agreements

Warrant Agreements	3 Months Ended
	Mar. 31, 2014
Notes to Financial Statements	'
NOTE 7 - Warrant Agreements	'
	On March 10, 2011 the Company issued a Promissory Note for $1,105,000 to St. George Investments along with 1,392,354 five year warrants at $0.01 per share.

	The Company has not issued any warrants since January 1, 2012.

	The following table summarizes the warrants outstanding and exercisable at March 31, 2014 (post split):

		WARRANTS OUTSTANDING		EXERCISE		MATURITY DATE
				PRICE
			1,392,354	$	0.01		3/10/16
	Total		1,392,354

Stockholders_Equity

Stockholder's Equity	3 Months Ended
Stockholder's Equity	Mar. 31, 2014
Notes to Financial Statements	'
NOTE 8 - Stockholder's Equity	'
	Preferred Stock

	CBAI has 5,000,000 shares of $.0001 par value preferred stock authorized.

	Common Stock

	On September 25, 2012, the Company’s Articles of Incorporation were amended to increase the authorized common stock to 890,000,000 shares, par value $0.0001, up from 250,000,000. This amendment was adopted by the Company’s Board of Directors on July 11, 2012, and its Shareholders at a Special Meeting of Shareholders called for this purpose on September 25, 2012.

	During the year ended December 31, 2013, the Company issued 513,765,592 shares of common stock to retire $776,502 of principal and interest in convertible debt which had a fair market value of $1,823,206.

	As of March 31, 2014 CBAI had 890,000,000 shares of Common Stock outstanding. 20,000 shares remain in the Company's treasury.

Segment_Reporting

Segment Reporting	3 Months Ended
Segment Reporting	Mar. 31, 2014
Notes to Financial Statements	'
NOTE 9 - Segment Reporting	'
	Note 9. Segment Reporting

	Guidance issued by the FASB requires that public business enterprises report financial and descriptive information about its reportable operating segments. Cord generates revenues related to the processing and preservation of umbilical cord blood. Cord’s long-lived assets are located in, and substantially all of its revenues are generated from, the United States of America and Argentina.

	The table below presents certain financial information by business segment for the three months ended March 31, 2014:

		Cord			Biocordcell		Segment			Consolidation		Condensed
							Total			Eliminations		Consolidated
												Total

	Revenue from External Customers	$	919,508		$	496,018		1,415,526		$	--	$	1,415,526
	Interest & Derivative Expense		171,391			27,891		199,282			--		199,282
	Depreciation and Amortization		134,199			46,942		181,141			--		181,141
	Segment Income (Loss)		-327,877			-217,604		(545,481	)		--		-545,481
	Segment Assets	$	4,404,627		$	1,609,734		6,014,361		$	-256,480	$	5,757,881

	The table below presents certain financial information by business segment for the three months ended March 31, 2013:

		Cord			Biocordcell		Segment			Consolidation		Condensed
							Total			Eliminations		Consolidated
												Total

	Revenue from External Customers	$	934,947		$	517,191	$	1,452,138		$	--	$	1,452,138
	Interest & Derivative Expense		488,668			4,328		492,996			--		492,996
	Depreciation and Amortization		180,561			12,836		193,397			--		193,397
	Segment Income (Loss)		(514,173	)		-73,747		(587,920	)		--		(587,920	)
	Segment Assets	$	4,643,277		$	1,775,924	$	6,419,201		$	-43,998	$	6,375,203

Subsequent_Events

Subsequent Events	3 Months Ended
Subsequent Events	Mar. 31, 2014
Notes to Financial Statements	'
NOTE 10 - Subsequent Events	'
	Frozen Food Gift Group
	Effective as of March 12, 2014 the Company entered into a Claim Purchase Agreement with a third party calling for payment by the third party to the Company in exchange for the Company’s claims against Frozen Food Gift Group, Inc. (“FFGG”), as set forth in a Mutual General Release described below (“Release”). Payment was made by the third party to the Company on or around April 1, 2014.

	The Company entered the Release with FFGG effective as of March 5, 2014, with the mutual releases and negative covenants contained therein not taking effect until such time as the Company received payment under the Claim Purchase Agreement as described above, which payment was made as mentioned above.

	Litigation versus Tonaquint, Inc. and St. George Investments, LLC

	As stated in Item 1. Legal Proceedings, on March 21, 2014, the Company filed a Motion for Leave to File Amended Complaint and Memorandum in the Action, seeking to amend its Complaint to add an additional claim for breach of contract, as well as a claim for promissory estoppel against Defendants. On May 6, 2014 the Court granted the Company’s Motion, and the Company filed its First Amended Complaint and Jury Demand on May 7, 2014.

Summary_of_Significant_Account1

Summary of Significant Accounting Policies (Policies)

3 Months Ended

Mar. 31, 2014

Summary Of Significant Accounting Policies Policies

Basis of Presentation and Going Concern

Basis of Consolidation

Deferred Revenue

Valuation of Derivative Instruments

Revenue Recognition

Impairment of Long-Lived Assets

Equity Investments

Fair Value Measurements

●

Level 1 – quoted prices in active markets for identical assets or liabilities.

●

Level 2 – other significant observable inputs for the assets or liabilities through corroboration with market data at the measurement date.

●

Level 3 – significant unobservable inputs that reflect management’s best estimate of what market participants would use to price the assets or liabilities at the measurement date.

The following table summarizes fair value measurements by level at March 31, 2014 of assets and liabilities measured at fair value on a recurring basis:

Level 1

Level 2

Level 3

Total

Cash and cash equivalents

802,496

—

802,496

Derivative liability

—

(388,507

)

(388,507

)

Derivative liability was valued under the Black-Scholes model, consistent with last year, with the following assumptions:

Risk free interest rate

0 to 0.13 %

Expected life

0 to 1 years

Dividend Yield

Volatility

0% to 112%

The following is a reconciliation of the derivative liability:

Value at December 31, 2013

359,407

Change in value of derivative

29,100

Value at March 31, 2014

388,507

Recently Issued Accounting Pronouncements

In February 2013, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") 2013-02, Reporting of Amounts Reclassified Out of Accumulated Other Comprehensive Income, ("ASU 2013-02"). ASU 2013-02 amends Accounting Standards Codification ("ASC") 220, Comprehensive income ("ASC 220"), and requires entities to present the changes in the components of accumulated other comprehensive income for the current period. Entities are required to present separately the amount of the change that is due to reclassifications, and the amount that is due to current period other comprehensive income. These changes are permitted to be shown either before or net-of-tax and can be displayed either on the face of the financial statements or in the footnotes. ASU 2013-02 was effective for our interim and annual periods beginning January 1, 2013. The adoption of ASU 2013-02 did not have a material effect on the Company's consolidated financial position or results of operations.

In March 2013, the FASB issued new guidance related to the release of cumulative translation adjustment related to an entity's investment in a foreign entity. The guidance clarifies that the guidance in Subtopic 830-30, Foreign Currency Matters - Translation of Financial Statements, applies to the release of cumulative translation adjustment into net income when a reporting entity either sells a part or all of its investment in a foreign entity or ceases to have a controlling financial interest in a subsidiary or group of assets that constitute a business within a foreign entity. This guidance is effective for us prospectively for reporting periods beginning October 1, 2014. The adoption of this guidance is not expected to have a material impact on the Company's consolidated financial statements.

Summary_of_Significant_Account2

Summary of Significant Accounting Policies (Tables)	3 Months Ended
Summary of Significant Accounting Policies (Tables)	Mar. 31, 2014
Summary Of Significant Accounting Policies Tables	'
Fair value measurements for assets and liabilities	'
		Level 1		Level 2		Level 3			Total

	Cash and cash equivalents	$	802,496	$	—	$	—		$	802,496

	Derivative liability	$	—	$	—	$	(388,507	)	$	(388,507	)
Derivative liability assumptions	'
	Risk free interest rate	0 to0.13 %
	Expected life	0 to 1 years
	Dividend Yield		0%
	Volatility	0% to 112%
Reconciliation of the derivative liability	'
	Value at December 31, 2013	$	359,407
	Change in value of derivative	$	29,100
	Value at March 31, 2014	$	388,507

Notes_and_loans_payable_Tables

Notes and loans payable (Tables)	3 Months Ended
	Mar. 31, 2014
Notes And Loans Payable Tables	'
Notes and loans payable	'

		March 31,			December 31,
		2014			2013

	Convertible Promissory Note Payable to St. George Investment, secured by the Company’s assets, interest rate of 6.0% per annum, with payment due on or before March 10, 2015		259,530			259,530
			1,252,000			1,252,000
	Secured Convertible Promissory Note to Tonaquint, Inc., 6% per annum; due on or before February 27, 2014
	(See Item 1. Legal Proceedings as described more fully)
			1,511,530			1,511,530
	Less: Unamortized Discount		(16,227	)		(70,195	)
		$	1,495,303		$	1,441,335

Commitments_and_Contingencies_

Commitments and Contingencies (Tables)	3 Months Ended
Commitments and Contingencies (Tables)	Mar. 31, 2014
Commitments And Contingencies Tables	'
Future minimum rental payments	'
		Rent
		to be paid
	2014	$	169,083
	2015		232,064
	2016		244,943
	2017		199,109
	2018		189,842
	Thereafter		153,902
	Total	$	1,188,943

Share_Based_Compensation_Table

Share Based Compensation (Tables)	3 Months Ended
Share Based Compensation (Tables)	Mar. 31, 2014
Notes to Financial Statements	'
Stock option activity	'
			Stock				Weighted Average Exercise Price				Weighted Avg. Contractual
			Options				Weighted Average Exercise Price				Remaining Life

	Outstanding, January 1, 2013			6,323,570				1.01				5.76
	Granted			-				-				-
	Exercised			-				-				-
	Forfeited/Expired			627,740				-				-
	Outstanding, December 31, 2013			5,570,830				1.01				4.51
	Exercisable at December 31, 2013			5,570,830				1.01				4.51
	Forfeited/Expired			-				-				-
	Outstanding, March 31, 2014			5,570,830				1.01
	Exercisable at March 31, 2014			5,570,830				1.01				4.26
Summary of significant ranges of outstanding stock options	'
	Range of				Number of				Weighted Average				Weighted Average		Number of		Weighted Average
	Exercise Prices				Options				Remaining				Exercise		Options		Exercise
									Contractual Life				Price		Exercisable		Price
									(years)
	$	0.33 — 20.00				5,522,806				4.28			$	0.83		5,522,806	$	0.83
	$	21.00 — 30.00				30,126				0.87				25		30,126		25
	$	31.00— 51.00				17,898				4.26				31.21		17,898		31.21
						5,570,830				4.26			$	1.01		5,570,830	$	1.01
Summary of the activity for unvested employee stock options	'
			Stock				Weighted Avg. Grant Date Fair Value per Share
			Options				Weighted Avg. Grant Date Fair Value per Share
	Nonvested at January 1, 2014			--				0.39
	Granted			--				--
	Vested			--				--
	Exercised			--				--
	Cancelled			--				--
	Pre-vested forfeitures			--				--
	Nonvested at March 31, 2014			--				0.39

Warrant_Agreements_Tables

Warrant Agreements (Tables)	3 Months Ended
	Mar. 31, 2014
Notes to Financial Statements	'
Summarizes of the warrants outstanding and exercisable	'
		WARRANTS OUTSTANDING		EXERCISE		MATURITY DATE
				PRICE
			1,392,354	$	0.01		3/10/16
	Total		1,392,354

Segment_Reporting_Tables

Segment Reporting (Tables)	3 Months Ended
Segment Reporting (Tables)	Mar. 31, 2014
Notes to Financial Statements	'
Financial information by business segment	'
	The table below presents certain financial information by business segment for the three months ended March 31, 2014:

		Cord			Biocordcell		Segment			Consolidation		Condensed
							Total			Eliminations		Consolidated
												Total

	Revenue from External Customers	$	919,508		$	496,018		1,415,526		$	--	$	1,415,526
	Interest & Derivative Expense		171,391			27,891		199,282			--		199,282
	Depreciation and Amortization		134,199			46,942		181,141			--		181,141
	Segment Income (Loss)		-327,877			-217,604		(545,481	)		--		-545,481
	Segment Assets	$	4,404,627		$	1,609,734		6,014,361		$	-256,480	$	5,757,881

	The table below presents certain financial information by business segment for the three months ended March 31, 2013:

		Cord			Biocordcell		Segment			Consolidation		Condensed
							Total			Eliminations		Consolidated
												Total

	Revenue from External Customers	$	934,947		$	517,191	$	1,452,138		$	--	$	1,452,138
	Interest & Derivative Expense		488,668			4,328		492,996			--		492,996
	Depreciation and Amortization		180,561			12,836		193,397			--		193,397
	Segment Income (Loss)		(514,173	)		-73,747		(587,920	)		--		(587,920	)
	Segment Assets	$	4,643,277		$	1,775,924	$	6,419,201		$	-43,998	$	6,375,203

Summary_of_Significant_Account3

Summary of Significant Accounting Policies (Details) (USD $)	Mar. 31, 2014
Fair Value, Measurements, Recurring [Member]	'
Summary of assets and liabilities measured at fair value on a recurring basis	'
Cash and cash equivalents	$802,496
Derivative liability	-388,507
Fair Value, Measurements, Recurring [Member], Level 1 [Member]	'
Summary of assets and liabilities measured at fair value on a recurring basis	'
Cash and cash equivalents	802,496
Derivative liability	0
Fair Value, Measurements, Recurring [Member], Level 2 [Member]	'
Summary of assets and liabilities measured at fair value on a recurring basis	'
Cash and cash equivalents	0
Derivative liability	0
Fair Value, Measurements, Recurring [Member], Level 3 [Member]	'
Summary of assets and liabilities measured at fair value on a recurring basis	'
Cash and cash equivalents	0
Derivative liability	($388,507)

Summary_of_Significant_Account4

Summary of Significant Accounting Policies (Details 1)	3 Months Ended
Summary of Significant Accounting Policies (Details 1)	Mar. 31, 2014
Dividend Yield	0.00%
Minimum [Member]	'
Risk free interest rate	0.00%
Expected life	'0 years
Volatility	0.00%
Maximum [Member]	'
Risk free interest rate	0.13%
Expected life	'1 year
Volatility	112.00%

Summary_of_Significant_Account5

Summary of Significant Accounting Policies (Details 2) (USD $)	3 Months Ended
	Mar. 31, 2014
Notes to Financial Statements	'
Value at Beginning	$359,407
Change in value of derivative	29,100
Value at Ending	$388,507

Summary_of_Significant_Account6

Summary of Significant Accounting Policies (Details Narrative) (USD $)	Mar. 31, 2014	Dec. 31, 2013
Notes to Financial Statements	'	'
Accumulated deficit	($54,122,144)	($53,685,436)
Notes and loans payable	$1,511,530	$1,511,530

Notes_and_Loans_Payable_Detail

Notes and Loans Payable (Details) (USD $)	Mar. 31, 2014	Dec. 31, 2013
Notes and loans payable	$1,511,530	$1,511,530
Less: Unamortized Discount	-16,227	-70,195
Notes and loans payable, Net	1,495,303	1,441,335
Convertible Promissory Note Payable To St George Investment [Member]	'	'
Notes and loans payable	259,530	259,530
Secured Convertible Promissory Note To Tonaquint [Member]	'	'
Notes and loans payable	$1,252,000	$1,252,000

Commitments_and_Contingencies_1

Commitments and Contingencies (Details Narrative) (USD $)	Mar. 31, 2014
St. George Investments	'
Principal balance due	$259,530
Accrued expenses	24,563
Tonaquint, Inc	'
Principal balance due	1,252,000
Accrued expenses	395,915
Patent License Agreement	'
Accounts payable	226,000
Accrued expenses	$120,000

Commitments_and_Contingencies_2

Commitments and Contingencies (Details) (USD $)	Mar. 31, 2014
Commitments And Contingencies Tables	'
2014	$169,083
2015	232,064
2016	244,943
2017	199,109
2018	189,842
Thereafter	153,902
Total	$1,188,943

Share_Based_Compensation_Detai

Share Based Compensation (Details) (USD $)	3 Months Ended	12 Months Ended
Share Based Compensation (Details) (USD $)	Mar. 31, 2014	Dec. 31, 2013
Share Based Compensation Details	'	'
Beginning Balance, shares	5,570,830	6,323,570
Begining Balance Exercisable, shares	5,570,830	5,570,830
Granted, shares	'	0
Exercised, shares	'	0
Forfeited/Expired, shares	0	627,740
Ending Balance, shares	5,570,830	5,570,830
Ending Balance Exercisable, shares	5,570,830	5,570,830
Beginning Balance, weighted average exercise price	$1.01	$1.01
Begining Balance Exercisable, weighted average exercise price	$1.01	'
Forfeited/Expired, weighted average exercise price	'	'
Ending Balance, weighted average exercise price	$1.01	$1.01
Ending Balance Exercisable, weighted average exercise price	$1.01	$1.01
Beginning Balance, Weighted Avg. Contractual Remaining Life (in years)	'4 years 6 months	'5 years 9 months 4 days
Begining Balance Exercisable, Weighted Avg. Contractual Remaining Life (in years)	'4 years 6 months	'
Ending Balance 2011, Weighted Avg. Contractual Remaining Life (in years)	'	'4 years 6 months
Ending Balance Exercisable 2012, Weighted Avg. Contractual Remaining Life (in years)	'4 years 3 months	'4 years 6 months

Share_Based_Compensation_Detai1

Share Based Compensation (Details 1) (USD $)	Mar. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Number of Options	5,570,830	5,570,830	6,323,570
Weighted Average Remaining Contractual Life (years)	'4 years 3 months	'	'
Weighted Average Exercise Price	$1.01	$1.01	$1.01
Number of Options Exercisable	5,570,830	5,570,830	5,570,830
Weighted Average Exercise Price	$1.01	$1.01	'
RangeOneMember	'	'	'
Range of Exercise Prices	'0.33 B 20.00	'	'
Number of Options	5,522,806	'	'
Weighted Average Remaining Contractual Life (years)	'4 years 3 months 11 days	'	'
Weighted Average Exercise Price	$0.83	'	'
Number of Options Exercisable	5,522,806	'	'
Weighted Average Exercise Price	$0.83	'	'
RangeTwoMember	'	'	'
Range of Exercise Prices	'21.00 B 30.00	'	'
Number of Options	30,126	'	'
Weighted Average Remaining Contractual Life (years)	'10 months 13 days	'	'
Weighted Average Exercise Price	$25	'	'
Number of Options Exercisable	30,126	'	'
Weighted Average Exercise Price	$25	'	'
RangeThreeMember	'	'	'
Range of Exercise Prices	'31.00B 51.00	'	'
Number of Options	17,898	'	'
Weighted Average Remaining Contractual Life (years)	'4 years 3 months	'	'
Weighted Average Exercise Price	$31.21	'	'
Number of Options Exercisable	17,898	'	'
Weighted Average Exercise Price	$31.21	'	'

Share_Based_Compensation_Detai2

Share Based Compensation (Details 2) (USD $)	3 Months Ended
Share Based Compensation (Details 2) (USD $)	Mar. 31, 2014
Share Based Compensation Details 2	'
Nonvested at January 1, 2014	0
Granted	0
Vested	0
Exercised	0
Cancelled	0
Pre-vested forfeitures	0
Nonvested at March 31, 2014	0
Nonvested at January 1, 2012	$0.39
Granted	'
Vested	'
Exercised	'
Cancelled	'
Pre-vested forfeitures	'
Nonvested at September 30, 2012	$0.39

Warrant_Agreements_Details

Warrant Agreements (Details) (USD $)	Mar. 31, 2014
Warrant Agreements Details	'
WARRANTS OUTSTANDING	1,392,354
EXERCISE PRICE	$0.01
MATURITY DATE	10-Mar-16

Stockholders_Equity_Details_Na

Stockholders Equity (Details Narrative) (USD $)	Mar. 31, 2014	Dec. 31, 2013
Stockholders Equity Details Narrative	'	'
Preferred stock authorized	5,000,000	5,000,000
Preferred stock, par value	$0.00	$0.00
Common Stock outstanding	890,000,000	890,000,000
Treasury stock	20,000	20,000

Segment_Reporting_Details

Segment Reporting (Details) (USD $)	3 Months Ended
Segment Reporting (Details) (USD $)	Mar. 31, 2014	Mar. 31, 2013
Revenue from external customer	$1,415,526	$1,452,138
Interest & Derivative Expense	199,282	492,996
Depreciation and Amortization	181,141	193,397
Segment Income (Loss)	-545,481	-587,920
Segment Assets	5,757,881	6,375,203
CordMember	'	'
Revenue from external customer	919,508	934,947
Interest & Derivative Expense	171,391	488,668
Depreciation and Amortization	134,199	180,561
Segment Income (Loss)	-327,877	-514,173
Segment Assets	4,404,627	4,643,277
BiocordcellMember	'	'
Revenue from external customer	496,018	517,191
Interest & Derivative Expense	27,891	4,328
Depreciation and Amortization	46,942	12,836
Segment Income (Loss)	-217,604	-73,747
Segment Assets	1,609,734	1,775,924
SegmentTotalMember	'	'
Revenue from external customer	1,415,526	1,452,138
Interest & Derivative Expense	199,282	492,996
Depreciation and Amortization	181,141	193,397
Segment Income (Loss)	-545,481	-587,920
Segment Assets	6,014,361	6,419,201
Consolidation Eliminations	'	'
Revenue from external customer	0	0
Interest & Derivative Expense	0	0
Depreciation and Amortization	0	0
Segment Income (Loss)	0	0
Segment Assets	($256,480)	($43,998)